A detailed history of Schonfeld Strategic Advisors LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 182,847 shares of DVAX stock, worth $2.01 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
182,847
Previous 130,502 40.11%
Holding current value
$2.01 Million
Previous $1.62 Million 26.81%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.73 - $12.58 $561,661 - $658,500
52,345 Added 40.11%
182,847 $2.05 Million
Q1 2024

May 15, 2024

SELL
$11.7 - $14.98 $544,096 - $696,629
-46,504 Reduced 26.27%
130,502 $1.62 Million
Q4 2023

Feb 14, 2024

BUY
$13.09 - $14.98 $2.32 Million - $2.65 Million
177,006 New
177,006 $2.47 Million
Q4 2022

Feb 14, 2023

SELL
$10.27 - $13.29 $104,240 - $134,893
-10,150 Reduced 17.58%
47,600 $506,000
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $573,457 - $1.01 Million
57,750 New
57,750 $603,000
Q2 2022

Aug 15, 2022

SELL
$7.45 - $12.83 $259,260 - $446,484
-34,800 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$9.75 - $14.44 $170,625 - $252,700
17,500 Added 101.16%
34,800 $377,000
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $227,841 - $362,262
17,300 New
17,300 $243,000
Q4 2020

Feb 16, 2021

SELL
$3.73 - $5.6 $316,430 - $475,070
-84,834 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.32 - $11.7 $366,482 - $992,557
84,834 New
84,834 $0
Q3 2018

Nov 14, 2018

SELL
$11.85 - $16.0 $569,985 - $769,600
-48,100 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$15.15 - $20.75 $330,148 - $452,184
21,792 Added 82.83%
48,100 $733,000
Q1 2018

May 15, 2018

BUY
$14.65 - $19.9 $23,571 - $32,019
1,609 Added 6.51%
26,308 $522,000
Q4 2017

Feb 14, 2018

BUY
$17.3 - $24.08 $427,292 - $594,751
24,699
24,699 $462,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.39B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.